<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00955942</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000644401</org_study_id>
    <secondary_id>UPCC-07507</secondary_id>
    <secondary_id>IRB# 806733</secondary_id>
    <nct_id>NCT00955942</nct_id>
  </id_info>
  <brief_title>Flaxseed Supplement in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Undergoing Chemotherapy and Radiation Therapy</brief_title>
  <official_title>A Phase I Blinded, Randomized Feasibility Trial of Dietary Flaxseed Administration in Non-Small Cell Lung Cancer Patients Receiving Definitive Thoracic Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Flaxseed may help&#xD;
      protect normal cells from the side effects of radiation therapy.&#xD;
&#xD;
      PURPOSE: This randomized phase I trial is studying the side effects of flaxseed supplement in&#xD;
      treating patients with locally advanced or metastatic non-small cell lung cancer undergoing&#xD;
      chemotherapy and radiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To assess the feasibility of dietary flaxseed (FS) supplementation in patients&#xD;
           undergoing definitive chemoradiotherapy for locally advanced or metastatic non-small&#xD;
           cell lung cancer.&#xD;
&#xD;
        -  To collect toxicity and tolerability data on dietary FS supplementation during&#xD;
           definitive chemoradiotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To validate urinary and serum markers of oxidative stress and FS lignan levels as&#xD;
           surrogates of the bioavailability of FS in these patients.&#xD;
&#xD;
        -  To determine if a dose response to daily ingestion of 20 g or 40 g of FS can be observed&#xD;
           in plasma lignan levels and urinary markers of oxidative stress.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients consume flaxseed muffins once or twice daily beginning on the first day&#xD;
           of radiotherapy and continuing for up to 9-10 weeks.&#xD;
&#xD;
        -  Arm II: Patients consume placebo muffins once or twice daily beginning on the first day&#xD;
           of radiotherapy and continuing for up to 9-10 weeks.&#xD;
&#xD;
      Blood and urine samples are collected periodically for biomarker studies.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 1 month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient enrollment&#xD;
  </why_stopped>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">June 2018</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of dietary flaxseed (FS) supplementation</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity and tolerability of dietary FS supplementation during chemoradiotherapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures of biomarkers of oxidative stress</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measures of serum levels of FS metabolites</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Radiation Toxicity</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients consume flaxseed muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients consume placebo muffins once or twice daily beginning on the first day of radiotherapy and continuing for up to 9-10 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>flaxseed</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of non-small cell lung cancer&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Requires definitive thoracic and mediastinal radiotherapy with concurrent chemotherapy&#xD;
&#xD;
               -  Total planned radiation dose to gross disease 60-80 Gy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  No diagnosis of disease of the gastrointestinal (GI) system, liver, or kidneys that&#xD;
             could result in altered metabolism or excretion of the study medication (e.g., history&#xD;
             of major GI tract surgery, gastrectomy, gastrostomy, or bowel resection)&#xD;
&#xD;
          -  No history of chronic GI disorders (e.g., ulcerative colitis, regional enteritis, or&#xD;
             GI bleeding)&#xD;
&#xD;
          -  No known hypersensitivity to flaxseed or any of its metabolites or to wheat products&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  See Patient Characteristics&#xD;
&#xD;
          -  More than 14 days since prior and no concurrent investigational drugs&#xD;
&#xD;
          -  More than 14 days since prior and no concurrent amifostine or Mucomyst&#xD;
             (N-acetylcysteine)&#xD;
&#xD;
          -  No prior thoracic radiotherapy&#xD;
&#xD;
          -  No prior or other concurrent flaxseed, flax-containing products, soybeans, or&#xD;
             soy-containing products&#xD;
&#xD;
          -  No other concurrent dietary supplements, such as herbals or botanicals&#xD;
&#xD;
               -  Vitamins or multivitamins, including calcium and vitamin D, are allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 7, 2009</study_first_submitted>
  <study_first_submitted_qc>August 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2009</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>radiation toxicity</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

